Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients

European Institute of Oncology114 enrolled

Overview

In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome. This information provides a rationale for the development of prophylactic strategies directed against chemotherapy-induced cardiotoxicity (CTIC). Activation of the renin-angiotensin system has been proved to be involved in the development and progression of cardiac dysfunction in several clinical settings, and has been suggested to have a role in the occurrence of CTIC. We investigated the role of treatment with ACE-inhibitors in the prevention of CTIC in high-risk cancer patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

114

Conditions

Cardiotoxicity Chemotherapeutic Toxicity

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Consecutive patients undergoing high-dose chemotherapy showing early release of Troponin I Exclusion Criteria: * Contraindication to ACE-inhibitors * On-going therapy with beta-blockers, ACE-inhibitors, angiotensin-receptors blockers

Outcomes

Primary Outcomes

Incidence of chemotherapy-induced cardiotoxicity

Time frame: 12 month period

Secondary Outcomes

Major adverse cardiac events, including death.